TITLE

PHASE 2 SHOWS IMPROVEMENT WITH MYDICAR FOR HEART FAILURE

PUB. DATE
July 2010
SOURCE
Worldwide Biotech;Jul2010, Vol. 22 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article deals with the results reported by Celladon Corp. in July 2010 from its Phase 2 clinical trial of Mydicar, a genetically targeted enzyme replacement therapy. Accordingly, the findings demonstrated the primary safety and efficacy endpoints for high dose Mydicar against placebo. Noted benefits in patients included significant reduction in cardiovascular events and improved exercise tolerance and cardiac function. Other details of the Calcium Up-regulation by Percutaneous administration of gene therapy in cardiac disease (CUPID) trial are cited.
ACCESSION #
51861711

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;5/24/2011, Vol. 22 Issue 100, p3 

    This section offers news briefs on several issues involving clinical trials. Anavex Life Sciences Corp. announced that the safety review committee for the Phase I trial of ANAVEX 2-73 approved skipping the dosage received by the volunteers to the 10 milligram (mg) dose cohort. Celladon Corp....

  • Gene Therapy for Heart Failure: Back to the Bench. Ylä-Herttuala, Seppo // Molecular Therapy;Oct2015, Vol. 23 Issue 10, p1551 

    The author reflects on the use of gene therapy for the treatment of heart failure. He mentions pharmaceutical firm Celladon Corp. which announced that its Mydicar adeno-associated viral vector 1 (AAV1)-expressing sarcoplasmic reticulum calcium ATPase drug for heart failure has failed in the...

  • A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Alton, Eric W. F. W.; Boyd, A. Christopher; Seng H. Cheng; Cunningham, Steve; Davies, Jane C.; Gill, Deborah R.; Griesenbach, Uta; Higgins, Tracy; Hyde, Stephen C.; Innes, J. Alastair; Murray, Gordon D.; Porteous, David J. // Thorax;Nov2013, Vol. 68 Issue 11, p1075 

    The UK Cystic Fibrosis Gene Therapy Consortium has been working towards clinical gene therapy for patients with cystic fibrosis for several years. We have recently embarked on a large, multi-dose clinical trial of a nonviral, liposome-based formulation powered for the first time to detect...

  • Is there a place for placebo controlled trials of antiepileptic drugs? Shorvon, S.D.; Espir, M.L.E.; Steiner, T.J.; Dellaportas, C.I.; Rose, F. Clifford // British Medical Journal (Clinical Research Edition);11/9/1985, Vol. 291 Issue 6505, p1328 

    Examines the possibility of a placebo controlled trials on antiepileptic drugs in Great Britain. Uncertainty on the role of anticonvulsant drugs on epileptics; Impact of epileptic seizures on the psychology and social behavior of epileptics; Natural history of epilepsy.

  • Withholding Proven Treatment in Clinical Research. Huston, Patricia; Peterson, Robert // New England Journal of Medicine;9/20/2001, Vol. 345 Issue 12, p912 

    Editorial. Discusses the ethics of placebo-controlled clinical trials. Role of the Declaration of Helsinki; Need for scientific and ethical justification of the use of placebos.

  • Is the Placebo Powerless? Hróbjartsson, Asbjørn; Gøtzsche, Peter C. // New England Journal of Medicine;05/24/2001, Vol. 344 Issue 21, p1594 

    Background: Placebo treatments have been reported to help patients with many diseases, but the quality of the evidence supporting this finding has not been rigorously evaluated. Methods: We conducted a systematic review of clinical trials in which patients were randomly assigned to either...

  • An Evaluation of Arbaprostil at Multiple Doses for the Treatment of Acute Duodenal Ulcer: A Randomized Double Blind Placebo-Controlled International Trial. Euler, A. R.; Krawiec, J.; Odes, H.; Gilat, T.; Garcia, L.; Rachmilewitz, D.; Gabryelewicz, A.; Gibinski, K.; Bass, D.; Barbara, L.; Porro, G. Bianchi; Lazzaroni, M.; Kirchmayer, S.; Nago-Nago, A.; Popiela, T.; Kulig, J.; Roca, M.; Hagenmuller, F.; Bergemann, W.; Schryver, M. // American Journal of Gastroenterology;Feb1990, Vol. 85 Issue 2, p145 

    Six hundred and thirty patients were enrolled in a randomized double-blind placebo-controlled trial evaluating two arbaprostil dosages (25 µg and 50 µg) qid for 4 wk for the treatment of acute duodonal ulcers. The healing rates in the placebo, 25-µg, and 50-µg treatment groups were...

  • Importance of Placebo Effect in Cough Clinical Trials. Eccles, Ron // Lung;Feb2010 Supplement 1, Vol. 188, p53 

    Cough is a unique symptom because, unlike sneeze and other symptoms, it can be under voluntary control and this complicates clinical trials on cough medicines. All over-the-counter cough medicines (OTC) are very effective treatments because of their placebo effect. The placebo effect is enhanced...

  • Growth hormone reduced HIV-related visceral fat.  // Hem/Onc Today;11/10/2008, Vol. 9 Issue 20, p40 

    The article discusses findings of a randomized, double-blind, placebo-controlled trial that was conducted by researchers from Massachusetts General Hospital in Boston, which examined the efficacy of low-dose growth hormone on body composition, glucose and cardiovascular factors as observed among...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics